Phanes Therapeutics reported positive phase 2 results for spevatamig (PT886), an anti‑CLDN18.2/CD47 bispecific antibody, in combination with chemotherapy for first‑line treatment of CLDN18.2‑positive metastatic pancreatic ductal adenocarcinoma (PDAC). Data presented at ASCO GI indicate the regimen produced responses that support further development in a difficult‑to‑treat disease. Spevatamig’s dual targeting (tumor antigen CLDN18.2 and innate immune checkpoint CD47) aims to combine direct tumor targeting with macrophage‑mediated phagocytosis. The phase 2 readout underlines the industry’s focus on bispecific modalities to engage the tumor microenvironment in solid tumors where monotherapies have limited efficacy. The company plans additional studies to confirm benefit and assess safety in larger cohorts; successful progression would add a differentiated immuno‑oncology candidate in a cancer type with few effective systemic options.